Drug
FS 069 clinical trials
- studies test it
- 19
- open now
- 0
- in phase 3
- 1
- first study started
- 2002
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 4 |
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 6
- Phase 3
- 1
- Phase 4
- 5
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 15
GE Healthcare (4) · Thomas Jefferson University (3) · University of Nebraska (2) · Mayo Clinic (2) · University of Utah (1) · Kassa Darge (1) · M.D. Anderson Cancer Center (1) · David Mooney (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses FS 069 is read from its arms, and is right about nine times in ten.
Testing it · 19
- Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver CancerCompletedPhase 2Thomas Jefferson UniversityNCT03199274Written as Perflutren Protein-Type A Microspheres
- Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization TreatmentCompletedPhase 2Thomas Jefferson UniversityNCT05328167Written as Perflutren Protein-Type A Microspheres
- Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following CryoablationCompletedPhase 2Thomas Jefferson UniversityNCT02440334Written as Optison
- Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing CryosurgeryWithdrawnEarly Phase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT02671552Written as Perflutren Protein-Type A Microspheres
- Regadenoson Real Time Perfusion Imaging Trial-OptisonCompletedPhase 3University of NebraskaNCT01489176Written as Regadenoson; Optison
- Detection of Coronary Stenosis With Intravenous MicrobubblesWithdrawnNot applicableUniversity of NebraskaNCT00580580Written as Optison
- Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of LymphedemaCompletedPhase 1Mayo ClinicNCT05613946Written as Optison
- Study to Determine Safety and Dosage of OPTISON in Pediatric ParticipantsCompletedPhase 4GE HealthcareNCT03740997Written as Optison
- IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?CompletedPhase 4Mayo ClinicNCT02625428Written as Optison
- Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial AppendageCompletedPhase 4University of UtahNCT01721447Written as Optison echocardiography contrast agent
- CeVUS With Intravesical Administration of OPTISON TM (Trademark) in ChildrenCompletedPhase 1/2Kassa DargeNCT02204917Written as OPTISON
- Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer PatientsCompletedNot applicableM.D. Anderson Cancer CenterNCT02321527Written as Perflutren Protein-Type A Microspheres Injectable Suspension
- Contrast Enhanced Ultrasound for Evaluation of Pediatric Abdominal TraumaCompletedPhase 1David MooneyNCT01763840Written as Contrast enhanced Ultrasound
- Contrast-Enhanced Ultrasound in Human Crohn's DiseaseWithdrawnPhase 1/2University of MichiganNCT02061163Written as Optison
- Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery DiseaseTerminatedPhase 2GE HealthcareNCT01394926Written as Optison
- 3-D Transcranial Ultrasound Analysis StudyCompletedNot applicableDuke UniversityNCT00239525Written as Perflutren Protein-Type A Microspheres for injection
- Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).CompletedPhase 4GE HealthcareNCT00878878Written as Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)
- A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.CompletedPhase 4GE HealthcareNCT00730964Written as Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)
- Determination of a Safe Dose of Optison in Pediatric Patients With Solid TumorsCompletedPhase 1St. Jude Children's Research HospitalNCT00186953Written as Optison
Codes
What other systems call FS 069 · ClinicalTrials.gg INT003903
- MeSH (NLM) C099458FS 069One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C099458 | FS 069 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.